信立泰连跌5天，中欧基金旗下1只基金位列前十大股东

Group 1 - The core point of the article highlights the recent decline in the stock price of Shenzhen Sinopharm Co., Ltd., which has dropped by 10.47% over five consecutive trading days [1] - Shenzhen Sinopharm Co., Ltd. was established in 1998 and went public in 2009, focusing on an integrated model of research, production, and sales in the pharmaceutical industry [1] - The company's major shareholder, China Europe Fund, reduced its holdings in the first quarter of this year, while the fund has achieved a year-to-date return of 9.28%, ranking 1497 out of 4529 in its category [1][2] Group 2 - The fund managers of China Europe Medical Health Mixed A are Ge Lan and Zhao Lei, with Ge Lan having a background in biomedical engineering and extensive experience in fund management since joining China Europe Fund in 2014 [3][4] - Zhao Lei, who has a master's degree and experience as a research analyst in the pharmaceutical sector, joined China Europe Fund in May 2021 and became a fund manager on July 4, 2025 [5] - China Europe Fund Management Co., Ltd. was established in July 2006 and has a diverse ownership structure, with significant stakes held by various entities including WP Asia Pacific Asset Management LLC and Guodu Securities [5]